We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Troglitazone reduces plasma levels of tumour necrosis factor-α in obese patients with type 2 diabetes.
- Authors
Katsuki, A.; Sumida, Y.; Murata, K.; Furuta, M.; Araki-Sasaki, R.; Tsuchihashi, K.; Hori, Y.; Yano, Y.; Gabazza, E. C.; Adachi, Y.
- Abstract
SummaryWe evaluated the effect of troglitazone (given orally 400 mg/day) on glucose intolerance and on the plasma levels of tumour necrosis factor-α (TNF-α) in 12 obese patients with type 2 diabetes for 12 weeks. Troglitazone significantly decreased fasting plasma glucose, serum C-peptide, serum insulin and HbA1c levels. Plasma levels of TNF-α were significantly reduced by troglitazone administered for 8 and 12 weeks. Troglitazone administration significantly improved insulin resistance, but did not affect pancreatic β-cell function as evaluated by the homeostasis model assessment (HOMA). In the present study, we reported for the first time that troglitazone administration significantly reduces plasma levels of TNF-α in obese patients with type 2 diabetes.
- Subjects
HYPOGLYCEMIC agents; TUMOR necrosis factors; TYPE 2 diabetes treatment
- Publication
Diabetes, Obesity & Metabolism, 2000, Vol 2, Issue 3, p189
- ISSN
1462-8902
- Publication type
Article
- DOI
10.1046/j.1463-1326.2000.00072.x